EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters

Megan Neary iD, Joanne Sharp iD, Eduardo Gallardo-Toledo, Joanne Herriott, Edyta Kijak, Chloe Bramwell iD, Helen Cox, Lee Tatham iD, Helen Box, Paul Curley, Usman Arshad, Rajith K R Rajoli und 9 weitere

Viruses · 2023

DOI: 10.3390/v15081744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Megan Neary und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L3 5TR, UK. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Medical Research Council, Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitro, but it has not been characterised for chemoprophylaxis in animal models. Clinically, nafamostat is limited to intravenous delivery and has an extremely short plasma half-life. This study sought to determine whether intranasal dosing of nafamostat at 5 mg/kg twice daily was able to prevent the airborne transmission of SARS-CoV-2 from infected to uninfected Syrian Golden hamsters. SARS-CoV-2 RNA was detectable in the throat swabs of the water-treated control group 4 days after cohabitation with a SARS-CoV-2 inoculated hamster. However, throat swabs from the intranasal nafamostat-treated hamsters remained SARS-CoV-2 RNA negative for the full 4 days of cohabitation. Significantly lower SARS-CoV-2 RNA concentrations were seen in the nasal turbinates of the nafamostat-treated group compared to the control (p = 0.001). A plaque assay quantified a significantly lower concentration of infectious SARS-CoV-2 in the lungs of the nafamostat-treated group compared to the control (p = 0.035). When taken collectively with the pathological changes observed in the lungs and nasal mucosa, these data are strongly supportive of the utility of intranasally delivered nafamostat for the prevention of SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AnimalsCricetinaeSARS-CoV-2RNA, ViralChemopreventionMesocricetusBenzamidinesGuanidines

Stichwörter der Autor:innen

SARS-CoV-2chemoprophylaxisnafamostat

Substanzen

RNA, ViralnafamostatBenzamidinesGuanidines

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L3 5TR, UK.
  • Centre of Excellence in Long-Acting Therapeutics (CELT), University of Liverpool, Liverpool L3 5TR, UK.
  • Translational Healthcare Technologies Group, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH10 5HF, UK.
  • Victor Phillip Dahdaleh Heart and Lung Research Institute, Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Papworth Road, Cambridge CB2 1BN, UK.
  • Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L3 5TR, UK.
  • Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland.

ORCID-Profile: Megan Neary, Joanne Sharp, Chloe Bramwell, Lee Tatham, Kevin Dhaliwal, Frank Mc Caughan, James Hobson, Anja Kipar, James P Stewart, Andrew Owen

Förderung

  • NIAID NIH HHS
  • Medical Research Council
  • Biotechnology and Biological Sciences Research Council
  • Unitaid
  • EPSRC
  • NIH
  • European Commission
  • MRC

Zitieren

APA

Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., Cox, H., Tatham, L., Box, H., Curley, P., Arshad, U., Rajoli, R. K. R., Pertinez, H., Valentijn, A., Dhaliwal, K., Mc Caughan, F., Hobson, J., Rannard, S., Kipar, A., …, & Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. Viruses. https://doi.org/10.3390/v15081744

Vancouver

Neary M, Sharp J, Gallardo-Toledo E, Herriott J, Kijak E, Bramwell C, et al. Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. Viruses. 2023. doi:10.3390/v15081744

BibTeX
@article{Neary2023,
  author = {Neary, Megan and Sharp, Joanne and Gallardo-Toledo, Eduardo and Herriott, Joanne and Kijak, Edyta and Bramwell, Chloe and Cox, Helen and Tatham, Lee and Box, Helen and Curley, Paul and Arshad, Usman and Rajoli, Rajith K R and Pertinez, Henry and Valentijn, Anthony and Dhaliwal, Kevin and Mc Caughan, Frank and Hobson, James and Rannard, Steve and Kipar, Anja and Stewart, James P and Owen, Andrew},
  title = {Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15081744}
}
Kostenlos starten →